Expected Moves

Potential strategic equity raise or dilutive financing around Q4 2026 to extend cash runway for QRX003, with the stock starting from an assumed $2.80 level after Q2 earnings.

Top-line Phase 2 efficacy and safety data for QRX003 in Netherton syndrome, a pivotal proof-of-concept event for Quoin, from an assumed $1.50 pre-readout price following a dilutive financing.

Q3 2026 earnings update, expected to focus on post-QRX003 data strategy, cash runway after any financing, and planning for next clinical steps, from an assumed $6.50 level if data are received positively.

Q4 2026 results and formal 2027 clinical outlook, including QRX003 regulatory plans and any new pipeline disclosures, from an assumed $3.75 share price.

Q1 2027 earnings call, expected to update investors on ongoing QRX003 development, broader pipeline progress, and cash needs into 2028, from an assumed $5.00 starting price.